Marksans Pharma Q1 FY27 Revenue Surges 35.6% to ₹841 Crore; PAT Jumps 173.9%
Marksans Pharma reported a strong Q1 FY27 with revenue up 35.6% to ₹841 crore. PAT surged 173.9% to ₹159 crore. Europe revenue grew 74.7% to ₹356 crore, driven by acquisitions like QliniQ B.V. North America contributed ₹377 crore. The company ended the quarter with ₹1,058 crore in cash.
The substantial revenue growth, record EBITDA and PAT, successful acquisitions, and strong cash position indicate a significant positive impact on the company's financial health and market position.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with strong performance in key regions and successful acquisitions, indicating a positive financial outlook.
Marksans Pharma announced a robust performance for the first quarter of FY27, with operating revenue soaring by 35.6% year-on-year to ₹841 crore. The company achieved its highest-ever quarterly EBITDA of ₹213 crore and Profit After Tax (PAT) of ₹159 crore, marking a significant 173.9% increase from the previous year.
The company's strategic investments in products, manufacturing, and international presence are yielding strong results. Europe emerged as a key growth driver, with revenues from the UK and Europe region reaching ₹356 crore, a 74.7% year-on-year increase. This growth was bolstered by the acquisition of QliniQ B.V. in the Netherlands, contributing ₹44 crore in revenue, and the impending consolidation of ABCnow GmbH in Germany.
North America remained the largest market, contributing ₹377 crore in revenue with a 15.1% year-on-year growth, despite softer seasonal demand. Australia and New Zealand also showed strong performance, with revenue up 53.7% year-on-year to ₹88 crore.
Gross profit increased by 38.9% to ₹497.3 crore, with gross margins improving to 59.1%. EBITDA margin expanded significantly to 25.3% from 16.1% in Q1 FY26, reflecting improved operational leverage. The company generated ₹185 crore in cash from operations, with free cash flow at ₹152 crore, and ended the quarter with a cash balance of ₹1,058 crore.
Looking ahead, Marksans Pharma is focused on scaling its presence across geographies, accelerating new product launches, particularly in Europe, and continuing to enhance profitability and cash generation. The company is also exploring further inorganic opportunities in Europe.
What to do with a filing like this
Marksans Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Marksans Pharma Limited. Read the original for the full detail.